Centile Bioscience Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- SaaS & Software
- Headquarters
- Bethesda, MD
- Street
- 5023 Wissioming Rd.
- Zip
- 20816
Offering
- Total offering
- $4.1M
- Amount sold
- $3.1M
- First sale
- Mar 20, 2026
- Min investment
- $0
- Securities
- Equity, Other
- Federal exemption
- Rule 506(b)
- Investors so far
- 3
How this filing compares
Ranked #106 of 244 SaaS & Software filings in April 2026 by offering amount.
Median SaaS & Software filing in April 2026: $4M. This offering is 1.0× the median.
Other Maryland filings this week: STANDARD VALUE LP, StepStone VC Secondaries Fund VII (Cayman) LP, StepStone VC Secondaries Fund VII LP, StepStone VC Secondaries Fund VII ND (Cayman) LP, StepStone VC Secondaries Fund VII ND LP
Leadership
Jakob Seidlitz — Executive Officer (also: Director)
Richard Bethlehem — Executive Officer
Joshua Bernstock — Executive Officer (also: Director)
L. Keith Mullins — Director
Hannah Mamuszka — Director
Filing details
Centile Bioscience Inc. filed a Form D with the SEC on April 16, 2026.